Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06623786
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-30
Brief Title:
Cancer Patient Remote Monitoring for Timely Communication Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Cancer Patient Remote Monitoring for Timely Communication Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONNECT
Brief Summary:
The study is designed as a prospective single-arm observational mixed-method study Patients with stage IV NSCLC or inoperable mesothelioma will be included and will be treated with immunotherapy according to current guidelines and standard of care Patients may receive either a PD1L1 inhibitor monotherapy or if indicated together with a CTLA4 inhibitor Immunotherapy may be administered alone or together with chemotherapy as per site standardphysicians choice Patients will be given access to a mobile app Patients will receive daily questions via the app to assess immune-related adverse events between clinic visits and their well-being
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None